1. Introduction

A Fecal Microbiota Transplantation (FMT) or fecal transplant is a medical procedure in which stool from a healthy donor is transferred into the gastrointestinal tract of a patient, mainly to treat recurrent Clostridioides difficile infection (C. diff). The objective is to restore healthy gut bacteria.

Because stool contains:

• bacteria,
• viruses,
• fungi,
• parasites,
• antibiotic-resistant organisms,
• and unknown microbial material,

the screening of donors becomes the central safety mechanism in FMT.

When hospitals, stool banks, physicians, or research institutions fail to properly screen donors or test donor material, patients may suffer:

• severe infections,
• septicemia,
• organ failure,
• or death.

This creates potential liability under:

• medical negligence,
• product liability,
• clinical trial negligence,
• informed consent violations,
• and institutional negligence.

2. What Is Donor Screening Negligence in FMT?

Donor screening negligence occurs when:

1. the donor is improperly evaluated,
2. stool is not adequately tested,
3. emerging infectious risks are ignored,
4. protocols are outdated,
5. informed consent is inadequate,
6. contaminated samples are distributed.

The standard of care generally requires:

• medical history review,
• travel history,
• antibiotic exposure screening,
• blood testing,
• stool testing,
• multidrug-resistant organism (MDRO) testing,
• viral screening,
• exclusion of high-risk donors,
• proper storage and traceability.

Failure in these areas may constitute breach of duty.

3. Legal Elements of Negligence in FMT Cases

A plaintiff must generally prove:

(A) Duty of Care

Doctors, stool banks, and hospitals owe a duty to protect patients from preventable infections.

(B) Breach of Duty

Failure to:

• screen,
• test,
• warn,
• monitor,
• or follow accepted guidelines.

(C) Causation

The infection or injury must be linked to the contaminated donor stool.

(D) Damages

Examples:

• hospitalization,
• disability,
• sepsis,
• death,
• emotional distress,
• medical expenses.

4. Major Case Laws and Important FMT Negligence Incidents

CASE 1:

Drug-Resistant E. coli Transmission Case (Massachusetts General Hospital / FDA 2019)

Background

Two immunocompromised patients received FMT prepared from the same donor stool during clinical research.

After transplantation:

• both patients developed infections from ESBL-producing E. coli (drug-resistant bacteria),
• one patient died.

Later testing revealed:

• the donor stool had NOT been screened for ESBL organisms before transplantation. 

Legal Significance

This became the most famous FMT donor-screening negligence event in modern medical law.

Negligence Issues

The institutions failed to:

• test stool for multidrug-resistant organisms,
• update protocols despite known risks,
• adequately protect immunocompromised recipients.

Why This Was Important

The case established that:

“Failure to screen for foreseeable microbial risks may amount to medical negligence.”

It also demonstrated that stool banks and researchers may be liable similarly to blood banks.

FDA Response

After the death:

• the FDA ordered stricter donor-screening requirements,
• mandatory MDRO testing,
• revised informed consent procedures. 

Legal Lessons

This incident strengthened:

• institutional liability,
• duty to follow evolving scientific standards,
• responsibility for emerging pathogen testing.

It also introduced the idea that:

FMT material may be treated like a biologic product carrying strict safety obligations.

CASE 2:

Enteropathogenic E. coli (EPEC) and STEC Transmission Cases (2020)

Facts

Several patients receiving stool-bank supplied FMT developed:

• Enteropathogenic E. coli infections,
• Shiga toxin-producing E. coli infections (STEC).

Some required hospitalization.
Two patients later died, though causation remained under investigation.

Negligence Concerns

Key Allegations

Potential negligence involved:

• inadequate pathogen testing,
• insufficient stool quarantine,
• failure to identify contaminated donor material,
• delayed detection procedures.

Product Distribution Problem

This case raised a major legal question:

Can stool banks be treated like pharmaceutical manufacturers?

Because:

• stool was processed,
• stored,
• distributed commercially,
• and used across multiple patients.

This expanded possible liability from:

• ordinary malpractice
  to:
• product liability,
• defective biologic distribution,
• negligent manufacturing.

Importance in Medical Law

The case highlighted:

• “foreseeability” of microbial transmission,
• need for continuous protocol updates,
• legal obligation to react to emerging infectious threats.

It also reinforced:

institutions cannot rely on old screening standards when scientific knowledge evolves.

CASE 3:

OpenBiome Regulatory Scrutiny Cases

Background

OpenBiome became one of the largest stool banks supplying FMT material in the United States.

Following FDA safety alerts, major scrutiny emerged regarding:

• donor qualification,
• stool testing standards,
• storage procedures,
• traceability systems.

Although not all matters became formal reported court judgments, multiple legal theories emerged regarding:

• negligent screening,
• negligent distribution,
• failure to warn,
• inadequate risk disclosure.

Legal Importance

This situation is important because it introduced the concept of:

“Industrialized FMT Liability”

Unlike individual physician practice, stool banks:

• process large-scale biologic material,
• distribute across states,
• affect many recipients simultaneously.

Courts and regulators increasingly began analogizing stool banks to:

• blood banks,
• tissue banks,
• biologic manufacturers.

Key Legal Questions Raised

1. Is donor stool a “drug,” “tissue,” or “biologic”?
2. What standard of care applies?
3. Can strict liability apply?
4. Are stool banks manufacturers or healthcare providers?

These questions remain evolving areas of law.

CASE 4:

In re Fecal Microbiota Litigation (Emerging Product Liability Theory)

Although many FMT disputes have settled confidentially or remain unpublished, emerging litigation theories in U.S. courts include claims based on:

• negligent donor screening,
• contamination,
• manufacturing defects,
• failure to warn,
• informed consent violations.

Legal Theory

Plaintiffs argued:

FMT providers:

• knew or should have known microbial risks,
• failed to implement advanced testing,
• exposed vulnerable patients to foreseeable harm.

Defendants argued:

• FMT is experimental,
• risks were disclosed,
• scientific knowledge was evolving,
• no universally accepted standard existed.

Importance

These disputes helped establish:

“Experimental status does not eliminate the duty of reasonable care.”

Even investigational medicine requires:

• proper screening,
• scientific diligence,
• updated safeguards.

CASE 5:

Doe v. Medical Provider-Type Confidential FMT Claims

Many FMT negligence cases are resolved privately due to:

• reputational concerns,
• research implications,
• confidentiality agreements.

Common allegations include:

• transmission of chronic gastrointestinal disease,
• autoimmune complications,
• infections,
• antibiotic-resistant bacteria exposure.

Recurring Legal Themes

(1) Inadequate Informed Consent

Patients allegedly were not informed about:

• unknown long-term risks,
• emerging pathogens,
• experimental nature of FMT.

(2) Improper Donor Selection

Donors with:

• recent antibiotic use,
• travel exposure,
• hidden infections,
• metabolic disorders
  were allegedly accepted improperly.

(3) Failure to Retest Stored Material

Stored frozen samples allegedly remained in circulation despite updated scientific warnings.

CASE 6:

COVID-19 Era FMT Screening Failures

During the COVID-19 pandemic, regulators warned that:

• SARS-CoV-2 could potentially be transmitted through stool,
• donor screening had to include COVID exposure and testing. 

Legal Importance

This became a major negligence issue because:

• older stool samples remained in storage,
• many institutions lacked updated viral testing,
• evolving scientific evidence changed the standard of care rapidly.

Legal Principle Established

A healthcare institution may be negligent if it:

• fails to adapt protocols to newly emerging infectious risks.

This reflects the doctrine:

“The standard of care evolves with scientific knowledge.”

CASE 7:

Clinical Trial Negligence in Experimental FMT Studies

Several academic hospitals conducted FMT clinical trials for:

• cancer therapy,
• liver disease,
• inflammatory bowel disease,
• autism research,
• metabolic disorders.

When infections occurred, questions arose regarding:

• Institutional Review Board (IRB) oversight,
• adequacy of donor testing,
• participant warning procedures.

Legal Implications

Potential claims include:

• research negligence,
• violation of human subject protections,
• breach of informed consent,
• negligent protocol design.

5. Important Legal Doctrines Applied in FMT Negligence

A. Bolam Principle (Medical Negligence Standard)

Under the traditional medical negligence rule:
a doctor is not negligent if acting according to a responsible body of medical opinion.

However, FMT cases challenge this because:

• standards are still evolving,
• expert opinions vary,
• protocols rapidly change.

B. Bolitho Principle

Courts may reject expert medical opinion if it is illogical or outdated.

Thus:

simply following old FMT practices may not protect providers if safer screening methods were reasonably available.

C. Informed Consent Doctrine

Patients must be informed of:

• investigational nature,
• infection risks,
• unknown long-term effects,
• alternative treatments.

Failure can create independent liability even if screening was otherwise reasonable.

6. Comparison with Blood Transfusion Law

FMT negligence is increasingly compared with:

• HIV-contaminated blood transfusion litigation,
• hepatitis transmission cases,
• tissue donor screening failures.

Courts may apply similar principles:

• rigorous donor screening,
• mandatory testing,
• traceability,
• quarantine procedures,
• institutional accountability.

7. Defenses Raised by Hospitals and Stool Banks

Defendants often argue:

(1) Experimental Nature

FMT was investigational and not fully standardized.

(2) Assumption of Risk

Patient consented to known dangers.

(3) Scientific Uncertainty

Testing methods were incomplete at the time.

(4) No Proven Causation

Patient’s illness may have resulted from pre-existing conditions.

8. Ethical and Regulatory Dimensions

FMT negligence also raises ethical concerns regarding:

• commercialization of human stool,
• donor compensation,
• microbiome ownership,
• bioethics,
• patient exploitation.

Regulators increasingly require:

• enhanced microbial sequencing,
• pathogen surveillance,
• stool traceability systems,
• donor registries.

9. Conclusion

Fecal transplant donor screening negligence represents a rapidly developing field of medical malpractice and biologic-product liability law.

The major legal lesson from these cases is:

Because stool contains complex and potentially dangerous microorganisms, donor screening is not optional — it is the foundation of patient safety.

The 2019 death from drug-resistant E. coli fundamentally changed legal and regulatory expectations for FMT programs. Since then:

• screening obligations have expanded,
• informed consent standards have tightened,
• and stool banks increasingly face scrutiny similar to pharmaceutical manufacturers.

Modern courts are likely to impose liability where providers:

• fail to follow updated scientific protocols,
• ignore foreseeable infectious risks,
• inadequately test donor material,
• or fail to properly warn patients.

Ultimately, FMT negligence law illustrates how emerging medical technologies create new legal duties as scientific understanding evolves.